Provided by Tiger Trade Technology Pte. Ltd.

Femasys Inc

0.5235
-0.0339-6.08%
Post-market: 0.52500.0015+0.29%19:58 EDT
Volume:587.79K
Turnover:305.33K
Market Cap:31.15M
PE:-0.76
High:0.5500
Open:0.5308
Low:0.5010
Close:0.5574
52wk High:1.63
52wk Low:0.3067
Shares:59.50M
Float Shares:49.76M
Volume Ratio:1.02
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6900
EPS(LYR):-0.8450
ROE:-376.23%
ROA:-69.37%
PB:6.84
PE(LYR):-0.62

Loading ...

Femasys Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
5 hours ago

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Yesterday

Femasys Amends Financing Terms and Issues New Warrants

TIPRANKS
·
Mar 21

BRIEF-Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026 - SEC Filing

Reuters
·
Mar 21

Femasys Inc - Amendment Removes Share Combination Event Adjustment in Notes and Warrants Effective Dec 31, 2025 - SEC Filing

THOMSON REUTERS
·
Mar 21

Femasys issues 16,378,563 unregistered Series D-1 warrants at $0.58 exercise price

Reuters
·
Mar 21

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 20

Femasys appoints Kenneth D. Eichenbaum to board of directors

Reuters
·
Mar 18

BRIEF-Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors

Reuters
·
Mar 18

Press Release: Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Dow Jones
·
Mar 18

Femasys Appoints DR. Kenneth D. Eichenbaum to Board of Directors

THOMSON REUTERS
·
Mar 18

Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices

Reuters
·
Mar 11

Femasys advances FemBloc to U.S. approval with initiation of trial enrollment

TIPRANKS
·
Mar 10

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

GlobeNewswire
·
Mar 10

Femasys Initiated at Buy by Lake Street

Dow Jones
·
Mar 04

Femasys initiated with a Buy at Lake Street

TIPRANKS
·
Mar 03

Femasys Grants 185,000 Stock Options to Two New Employees Under Nasdaq Rule 5635(c)(4)

Reuters
·
Feb 28

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 28

Femasys’s FemBloc Pivotal Trial Update: What Investors Should Watch in Women’s Health

TIPRANKS
·
Feb 28

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

GlobeNewswire
·
Feb 26